Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam)
- 1 February 2005
- Vol. 65 (2), 343-346
- https://doi.org/10.1016/j.urology.2004.09.046
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands)BJU International, 2003
- The story of the European Randomized Study of Screening for Prostate CancerBJU International, 2003
- Possibility of re‐screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or lessThe Prostate, 2003
- Natural history of PSA increase with and without prostate cancerUrology, 2003
- Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate CancerJNCI Journal of the National Cancer Institute, 2003
- Prostate Specific Antigen Based Biennial Screening is Sufficient to Detect Almost All Prostate Cancers While Still CurableJournal of Urology, 2003
- Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, AustriaUrology, 2001
- Prostate-specific antigen-based early detection of prostate cancer—validation of screening without rectal examinationUrology, 2001
- Evaluation of the Digital Rectal Examination as a Screening Test for Prostate CancerJNCI Journal of the National Cancer Institute, 1998
- Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocityUrology, 1995